• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Natera, Inc. - Common Stock (NQ:NTRA)

    198.93 +5.71 (+2.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Natera, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
    From Natera, Inc.
    Via Business Wire
    Natera to Report its Third Quarter Results on November 6, 2025
    From Natera, Inc.
    Via Business Wire
    Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
    From Natera, Inc.
    Via Business Wire
    How Do Investors Really Feel About Natera?
     
    Via Benzinga
    Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    A Glimpse Into The Expert Outlook On Natera Through 8 Analysts
     
    Via Benzinga
    Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
    As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
    Via StockStory
    Topics Artificial Intelligence
    Why Are Natera (NTRA) Shares Soaring Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.2% in the afternoon session after the company announced promising results from its phase 3 IMvigor011 clinical trial for its Signatera... 
    Via StockStory
    Topics Intellectual Property
    Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
    From Natera, Inc.
    Via Business Wire
    Natera Named to Fast Company’s Next Big Things in Tech List
    From Natera, Inc.
    Via Business Wire
    Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
     
    Via Benzinga
    Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
    From Natera, Inc.
    Via Business Wire
    Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
    From Natera, Inc.
    Via Business Wire
    2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 That Underwhelm
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
    Via StockStory
    Topics Retirement
    Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
    From Natera, Inc.
    Via Business Wire
    Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
    From Natera, Inc.
    Via Business Wire
    Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
    From Natera, Inc.
    Via Business Wire
    2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds
    A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
    Via StockStory
    Stocks making big moves yesterday: Acadia Healthcare, Tesla, THOR Industries, Natera, and P10
    Check out the companies making headlines yesterday: 
    Via StockStory
    Topics Electric Vehicles
    Here's How Much $1000 Invested In Natera 5 Years Ago Would Be Worth Today
     
    Via Benzinga
    Why Natera (NTRA) Stock Is Down Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.5% in the afternoon session after Wells Fargo & Company initiated coverage on the stock with a neutral "equal weight" rating and set a... 
    Via StockStory
    Topics Artificial Intelligence Lawsuit
    Deep Dive Into Natera Stock: Analyst Perspectives (6 Ratings)
     
    Via Benzinga
    If You Invested $100 In Natera Stock 5 Years Ago, You Would Have This Much Today
     
    Via Benzinga
    2 Unprofitable Stocks on Our Watchlist and 1 We Ignore
    Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
    Via StockStory
    Why Natera (NTRA) Stock Is Trading Lower Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v.... 
    Via StockStory
    Topics Artificial Intelligence Lawsuit
    Why Natera (NTRA) Shares Are Falling Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood... 
    Via StockStory
    Topics Intellectual Property
    3 Reasons We’re Fans of Natera (NTRA)
    Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its... 
    Via StockStory
    Topics Stocks
    1 Cash-Producing Stock to Own for Decades and 2 We Find Risky
    A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
    Via StockStory
    Topics Supply Chain
    Why Natera (NTRA) Stock Is Down Today
    Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor... 
    Via StockStory
    Topics Intellectual Property
    NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims
    NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boosting investor sentiment. 
    Via Benzinga
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.